Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 4/20 | 0.47 |
| ▸ | MMP3 | P08254 | 4/20 | 0.47 |
| ▸ | MMP9 | P14780 | 4/20 | 0.47 |
| ▸ | MMP13 | P45452 | 4/20 | 0.47 |
| ▸ | MMP1 | P03956 | 3/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 9/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875463 | 0.91 | PPARG (0.53) | PPARGPPARAMMP2MMP3MMP9 | |
| SCHEMBL875126 | 0.86 | MMP2 (0.59) | PPARGPPARAMMP2MMP3MMP9 | |
| SCHEMBL877491 | 0.84 | MMP2 (0.46) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL874780 | 0.82 | PPARG (0.49) | PPARGPPARAMMP2MMP3MMP9 | |
| SCHEMBL15735059 | 0.82 | GPR139 (0.49) | PPARGPPARAMMP2MMP3MMP9 | |
| SCHEMBL877754 | 0.82 | GPR139 (0.49) | PPARGPPARAMMP2MMP3MMP9 | |
| SCHEMBL874630 | 0.82 | MMP2 (0.47) | PPARGPPARAMMP2MMP3MMP9 | |
| SCHEMBL877119 | 0.82 | MMP2 (0.52) | PPARGPPARAMMP2MMP3MMP9 | |
| SCHEMBL15733192 | 0.82 | MMP2 (0.52) | PPARGPPARAMMP2MMP3MMP9 | |
| SCHEMBL874496 | 0.81 | MMP2 (0.51) | MMP2MMP3MMP9MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | claimed |
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| EP-2619185-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038942-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP12, MMP10 | PPARG 891/4885PPARA 1792/4885MMP2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.